Regenxbio Q2 2024 GAAP EPS $(1.05) Beats $(1.29) Estimate, Sales $22.295M Miss $22.973M Estimate
Portfolio Pulse from Benzinga Newsdesk
Regenxbio (NASDAQ:RGNX) reported Q2 2024 GAAP EPS of $(1.05), beating the $(1.29) estimate, but missed sales estimates with $22.295M against $22.973M. EPS improved by 36.75% YoY, and sales increased by 11.60% YoY.
August 01, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio reported Q2 2024 GAAP EPS of $(1.05), beating the $(1.29) estimate, but missed sales estimates with $22.295M against $22.973M. EPS improved by 36.75% YoY, and sales increased by 11.60% YoY.
Regenxbio's better-than-expected EPS and significant YoY improvement in both EPS and sales are positive indicators. However, the slight miss on sales estimates may temper the overall positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100